BioViva Achieves Patent for Revolutionary Klotho Gene Therapy Against Cognitive Decline
BioViva USA, Inc., a pioneering biotechnology company focused on combating the effects of aging, has recently announced a significant milestone in its research efforts. The company was awarded U.S. Patent No. 12,564,646 on March 3, 2026, which outlines the application of gene therapy to address age-related cognitive decline utilizing human Klotho and telomerase reverse transcriptase (hTERT). This innovative approach targets a pressing health issue: the cognitive impairments associated with aging, including conditions like dementia and Alzheimer's disease.
The significance of Klotho, a naturally occurring protein linked to healthy aging and neurological function, underscores the innovative nature of this patent. Instead of merely developing treatments to supplement Klotho levels in the body, BioViva's strategy focuses on enabling cells to produce Klotho on their own through gene therapy. This methodology represents a potential paradigm shift in how we approach age-related cognitive decline, moving from treatment to prevention.
The newly granted patent encompasses various gene delivery systems, particularly highlighting the potential of viral-vector technologies. Among the specifics detailed within the patent is the use of AAV8 and AAV9 vectors administered intranasally to effectively deliver Klotho and hTERT directly to the brain. By facilitating this direct approach, BioViva aims to maximize the brain’s uptake of these therapeutic agents, which can significantly enhance cognitive performance and potentially mitigate the progression of age-related cognitive conditions.
Elizabeth Parrish, CEO of BioViva USA, expressed her enthusiasm regarding the patent’s issuance, stating, "This patent represents an important milestone for BioViva and advances our ongoing endeavor to tackle the biology underpinning age-related diseases. Klotho has stood out in our research as a critical gene linked to the processes of healthy aging. Our aim is to develop therapies that target the core biological mechanisms causing aging rather than solely focusing on the diseases that emerge as a consequence."
This patent not only fortifies BioViva's intellectual property portfolio but also lays the groundwork for exciting future opportunities. The company is currently pursuing patent applications in both the European Union and China. These pending applications signify BioViva’s commitment to advancing its reach and addressing age-related cognitive decline on a global scale. The outcome of these applications will be closely monitored as BioViva seeks to expand its international presence in this promising field.
BioViva's dedication to exploring innovative gene therapies reflects its broader mission: to identify and target the biological mechanisms associated with aging. The company’s strategy encompasses a comprehensive study of the hallmarks of aging and aims to develop interventions that may ultimately promote a longer, healthier human lifespan.
As this area of research continues to evolve, BioViva stands at the forefront, making strides that hold the potential to transform how we understand aging and cognitive health. Clinicians and researchers alike will eagerly await the outcomes of ongoing clinical developments tied to this groundbreaking patent, as well as prospective collaborative efforts harnessing the potential of Klotho-based therapies. For further inquiries or information regarding BioViva’s advancements, please reach out to their media contact at BioViva USA, Inc.
With exciting avenues unfolding, BioViva looks poised not only to influence the landscape of cognitive health but also to contribute significantly to the emerging field of longevity science. Their commitment to innovation and exploration in this pivotal area of biomedicine makes them a company to watch in the coming years.
The significance of Klotho, a naturally occurring protein linked to healthy aging and neurological function, underscores the innovative nature of this patent. Instead of merely developing treatments to supplement Klotho levels in the body, BioViva's strategy focuses on enabling cells to produce Klotho on their own through gene therapy. This methodology represents a potential paradigm shift in how we approach age-related cognitive decline, moving from treatment to prevention.
The newly granted patent encompasses various gene delivery systems, particularly highlighting the potential of viral-vector technologies. Among the specifics detailed within the patent is the use of AAV8 and AAV9 vectors administered intranasally to effectively deliver Klotho and hTERT directly to the brain. By facilitating this direct approach, BioViva aims to maximize the brain’s uptake of these therapeutic agents, which can significantly enhance cognitive performance and potentially mitigate the progression of age-related cognitive conditions.
Elizabeth Parrish, CEO of BioViva USA, expressed her enthusiasm regarding the patent’s issuance, stating, "This patent represents an important milestone for BioViva and advances our ongoing endeavor to tackle the biology underpinning age-related diseases. Klotho has stood out in our research as a critical gene linked to the processes of healthy aging. Our aim is to develop therapies that target the core biological mechanisms causing aging rather than solely focusing on the diseases that emerge as a consequence."
This patent not only fortifies BioViva's intellectual property portfolio but also lays the groundwork for exciting future opportunities. The company is currently pursuing patent applications in both the European Union and China. These pending applications signify BioViva’s commitment to advancing its reach and addressing age-related cognitive decline on a global scale. The outcome of these applications will be closely monitored as BioViva seeks to expand its international presence in this promising field.
BioViva's dedication to exploring innovative gene therapies reflects its broader mission: to identify and target the biological mechanisms associated with aging. The company’s strategy encompasses a comprehensive study of the hallmarks of aging and aims to develop interventions that may ultimately promote a longer, healthier human lifespan.
As this area of research continues to evolve, BioViva stands at the forefront, making strides that hold the potential to transform how we understand aging and cognitive health. Clinicians and researchers alike will eagerly await the outcomes of ongoing clinical developments tied to this groundbreaking patent, as well as prospective collaborative efforts harnessing the potential of Klotho-based therapies. For further inquiries or information regarding BioViva’s advancements, please reach out to their media contact at BioViva USA, Inc.
With exciting avenues unfolding, BioViva looks poised not only to influence the landscape of cognitive health but also to contribute significantly to the emerging field of longevity science. Their commitment to innovation and exploration in this pivotal area of biomedicine makes them a company to watch in the coming years.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.